We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+34.71%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.61B
AUM Growth
+$411M
Cap. Flow
+$88.5M
Cap. Flow %
5.49%
Top 10 Hldgs %
79.5%
Holding
39
New
7
Increased
9
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
GH icon
Guardant Health
GH
+$25M
2
TXG icon
10x Genomics
TXG
+$21.1M
3
DNLI icon
Denali Therapeutics
DNLI
+$16M
4
LAB icon
Standard BioTools
LAB
+$15.1M
5
RLAY icon
Relay Therapeutics
RLAY
+$11.9M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$50.4M
2
BLFS icon
BioLife Solutions
BLFS
+$19.6M
3
GPCR icon
Structure Therapeutics
GPCR
+$15.5M
4
EXAS
Exact Sciences
EXAS
+$4.92M
5
RVMD icon
Revolution Medicines
RVMD
+$4.59M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WGS icon
1
GeneDx Holdings
WGS
$1.84B
$391M 24.29%
3,007,164
– –
RVMD icon
2
Revolution Medicines
RVMD
$39.1B
$205M 12.75%
2,577,333
-70,000
-3% -$4.59M
BLFS icon
3
BioLife Solutions
BLFS
$1.56B
$144M 8.95%
5,957,165
-750,000
-11% -$19.6M
LAB icon
4
Standard BioTools
LAB
$311M
$114M 7.06%
88,783,856
+11,225,000
+14% +$15.1M
RLAY icon
5
Relay Therapeutics
RLAY
$3.99B
$110M 6.83%
13,003,574
+1,662,193
+15% +$11.9M
GPCR icon
6
Structure Therapeutics
GPCR
$3.4B
$81.7M 5.08%
1,175,000
-380,000
-24% -$15.5M
ILMN icon
7
Illumina
ILMN
$29.2B
$78.7M 4.89%
600,000
+75,000
+14% +$8.8M
RNAM
8
DELISTED
Avidity Biosciences
RNAM
$72.1M 4.48%
1,000,000
-780,000
-44% -$50.4M
BEAM icon
9
Beam Therapeutics
BEAM
$2.7B
$44.4M 2.75%
1,600,000
– –
GH icon
10
Guardant Health
GH
$19B
$38.8M 2.41%
380,000
+280,000
+280% +$25M
MAZE
11
Maze Therapeutics
MAZE
$1.54B
$31.4M 1.95%
758,857
– –
DNLI icon
12
Denali Therapeutics
DNLI
$3.82B
$30.4M 1.89%
1,840,000
+950,000
+107% +$16M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$38.5B
$29.8M 1.85%
75,000
+20,000
+36% +$8.85M
NGNE icon
14
Neurogene
NGNE
$663M
$26.7M 1.66%
1,295,361
– –
TXG icon
15
10x Genomics
TXG
$5.97B
$22.8M 1.42%
+1,400,000
New +$21.1M
SPRY icon
16
ARS Pharmaceuticals
SPRY
$563M
$18.6M 1.16%
1,600,000
– –
TEM
17
Tempus AI
TEM
$7.72B
$17.4M 1.08%
294,127
– –
UNH icon
18
UnitedHealth
UNH
$389B
$16.5M 1.03%
50,000
+25,000
+100% +$8.47M
SEPN
19
Septerna Inc
SEPN
$1.53B
$15.4M 0.96%
553,268
– –
HIMS icon
20
Hims & Hers Health
HIMS
$6.79B
$12.5M 0.78%
385,000
+155,000
+67% +$6.64M
VCYT icon
21
Veracyte
VCYT
$4.44B
$11.6M 0.72%
276,308
– –
DXCM icon
22
DexCom
DXCM
$28.9B
$11.6M 0.72%
+175,000
New +$11.3M
SRRK icon
23
Scholar Rock
SRRK
$5.92B
$11.5M 0.71%
+260,000
New +$9.75M
CI icon
24
Cigna
CI
$79.6B
$11M 0.68%
+40,000
New +$11.2M
PRME icon
25
Prime Medicine
PRME
$558M
$11M 0.68%
3,167,175
– –
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
GSEP
Golden State Equity Partners South Coast Metro, California $1.32B AUM 23.87% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.32B AUM 24.91% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return

Casdin Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Casdin Capital held 39 positions worth $1.61B, up 34% from $1.2B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Casdin Capital deployed $88.5M of net new capital in Q4 2025, opening 7 new positions and adding to 9 existing holdings. Its largest new stake was 10x Genomics: 1,400,000 shares worth $22.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Avidity Biosciences, an estimated $50.4M trimmed.

  • Casdin Capital's largest Q4 2025 buy was 10x Genomics: 1,400,000 shares worth $22.8M.
  • Casdin Capital added most to Guardant Health in Q4 2025, an estimated $25M increase.
  • Casdin Capital's biggest Q4 2025 reduction was Avidity Biosciences, cutting an estimated $50.4M.
  • Casdin Capital fully exited Exact Sciences in Q4 2025, selling an estimated $4.92M.
  • Casdin Capital's ten largest holdings make up 79% of its $1.61B portfolio in Q4 2025.
  • Casdin Capital opened 7 new positions and closed 1 in Q4 2025.
  • Casdin Capital's portfolio value rose 34% quarter-over-quarter to $1.61B.

Based on Casdin Capital's 13F filing for Q4 2025, filed 17 Feb 2026.